Browse Studies — Arctuva

Phase 1

A Multicenter, Multi-Part, Phase 1/2 Study of EIK1005 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors, Including Checkpoint Inhibitor Naïve Participants With Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Tumors

The goal of this clinical trial is to determine the most effective dose of EIK1005 that a person can take safely. Additionally, this study will test how well E…

Advanced Solid TumorsMSI-H or dMMR Advanced Solid TumorsMSI-H/dMMR Gastric Cancer+4 more

Estimated

~$10 – $8,750

Eikon TherapeuticsNCT07262619

Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies

This study will collect tumor specimens with correlated clinical and demographic data from patients who are undergoing a biopsy or similar procedure to obtain …

CancerImmunotherapyAdvanced Solid Tumors Cancer+12 more

Estimated

~$10 – $1,125

ElephasNCT07327489

Phase 2

Phase II, Single Arm Study of Neoadjuvant Dostarlimab (TSR-042) in Stage II and III Deficient Mismatch Repair Colon Cancers

This is a Phase II, single arm study looking at the rate of major clinical response and non-operative management in Stage II and III colon cancer after 18 week…

Colon CancerdMMR Colorectal Cancer

Estimated

~$10 – $6,250

University of IowaNCT05239546